Knockdown of FBXO39 inhibits proliferation and promotes apoptosis of human osteosarcoma U‑2OS cells

Zheng,Jianrong; You,Wei; Zheng,Chuanxi; Wan,Peng; Chen,Jinquan; Jiang,Xiaochun; Zhu,Zhixiang; Zhang,Zhixiong; Gong,Anqi; Li,Wei; Tan,Jifeng; Ji,Tao; Guo,Wei; Zhang,Shiquan

doi:10.3892/ol.2018.8876

Knockdown of FBXO39 inhibits proliferation and promotes apoptosis of human osteosarcoma U‑2OS cells

Authors:
- Jianrong Zheng
- Wei You
- Chuanxi Zheng
- Peng Wan
- Jinquan Chen
- Xiaochun Jiang
- Zhixiang Zhu
- Zhixiong Zhang
- Anqi Gong
- Wei Li
- Jifeng Tan
- Tao Ji
- Wei Guo
- Shiquan Zhang
View Affiliations

Affiliations: Department of Joint and Musculoskeletal Tumor, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518000, P.R. China, Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, P.R. China
Published online on: June 1, 2018 https://doi.org/10.3892/ol.2018.8876
Pages: 1849-1854

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

F‑box proteins are essential components of the Skp‑cullin‑F‑box complex (a type of E3 ubiquitin ligase), and participate in cell cycle and immune responses through the ubiquitin proteasome system. F‑box protein 39 (FBXO39) belongs to the F‑box family, which has been reported to be associated with cancer oncogenesis and progression. The present study aimed to investigate the role of FBXO39 in osteosarcoma (OS) cell proliferation and apoptosis in vitro. It was demonstrated that U‑2OS cells exhibited high expression of FBXO39 compared with HOS and SaOS‑2 osteosarcoma cells. Thus, knockdown of FBXO39 was performed using lentivirus‑mediated short hairpin RNA (shRNA) transfection to validate the effect of FBXO39 in U‑2OS cells. Western blotting and RT‑qPCR analysis were used to confirm the efficiency of infection by analyzing the expression level of FBXO39. Using Celigo‑based cell counting and MTT assays, it was demonstrated that FBXO39 knockdown significantly reduced the rate of cell proliferation compared with control. Caspase 3/7 activity assays and fluorescence‑activated cell sorting confirmed the induction of apoptosis in U‑2OS cells following FBXO39 knockdown. In conclusion, it was demonstrated that FBXO39 knockdown may significantly inhibit proliferation and promote apoptosis of U‑2OS cells. Thus, FBXO39 may serve an important role in OS progression.

View Figures

View References

1	Moore DD and Luu HH: Osteosarcoma. Cancer Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
2	Heare T, Hensley MA and Dell'Orfano S: Bone tumors: Osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr. 21:365–372. 2009. View Article : Google Scholar : PubMed/NCBI
3	Caudill JS and Arndt CA: Diagnosis and management of bone malignancy in adolescence. Adolesc Med State Art Rev. 18:62–78, ix. 2007.PubMed/NCBI
4	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ando K, Heymann MF, Stresing V, Mori K, Rédini F and Heymann D: Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013. View Article : Google Scholar : PubMed/NCBI
7	Bridge JA, Nelson M, McComb E, McGuire MH, Rosenthal H, Vergara G, Maale GE, Spanier S and Neff JR: Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet. 95:74–87. 1997. View Article : Google Scholar : PubMed/NCBI
8	Helman LJ and Meltzer P: Mechanisms of sarcoma development. Nat Rev Cancer. 3:685–694. 2003. View Article : Google Scholar : PubMed/NCBI
9	Basu-Roy U, Basilico C and Mansukhani A: Perspectives on cancer stem cells in osteosarcoma. Cancer Lett. 338:158–167. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kipreos ET and Pagano M: The F-box protein family. Genome Biol. 1:REVIEWS3002. 2000. View Article : Google Scholar : PubMed/NCBI
11	Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M and Harper JW: Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 18:2573–2580. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ho MS, Ou C, Chan YR, Chien CT and Pi H: The utility F-box for protein destruction. Cell Mol Life Sci. 65:1977–2000. 2008. View Article : Google Scholar : PubMed/NCBI
13	Uddin S, Bhat AA, Krishnankutty R, Mir F, Kulinski M and Mohammad RM: Involvement of F-BOX proteins in progression and development of human malignancies. Semin Cancer Biol. 36:18–32. 2016. View Article : Google Scholar : PubMed/NCBI
14	Song MH, Ha JC, Lee SM, Park YM and Lee SY: Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun. 408:195–201. 2011. View Article : Google Scholar : PubMed/NCBI
15	Seifi-Alan M, Shamsi R, Ghafouri-Fard S, Mirfakhraie R, Zare-Abdollahi D, Movafagh A, Modarressi MH, Kazemi G, Geranpayeh L and Najafi-Ashtiani M: Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev. 14:6625–6629. 2014. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Nabzdyk CS, Chun M, Pradhan L and Logerfo FW: High throughput RNAi assay optimization using adherent cell cytometry. J Transl Med. 9:482011. View Article : Google Scholar : PubMed/NCBI
18	Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D and Eccles SA: Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 10:292012. View Article : Google Scholar : PubMed/NCBI
19	Moodley S, Koorbanally NA, Moodley T, Ramjugernath D and Pillay M: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay is a rapid, cheap, screening test for the in vitro anti-tuberculous activity of chalcones. J Microbiol Methods. 104:72–78. 2014. View Article : Google Scholar : PubMed/NCBI
20	Pan Y, Shan W, Fang H, Guo M, Nie Z, Huang Y and Yao S: Sensitive and visible detection of apoptotic cells on Annexin-V modified substrate using aminophenylboronic acid modified gold nanoparticles (APBA-GNPs) labeling. Biosens Bioelectron. 52:62–68. 2014. View Article : Google Scholar : PubMed/NCBI
21	Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W, Dierkes C, et al: Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res. 16:4256–4267. 2010. View Article : Google Scholar : PubMed/NCBI
22	Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, Rodda SJ, Snay E, Dunning P, Fahey FH, et al: Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 22:1662–1676. 2008. View Article : Google Scholar : PubMed/NCBI
23	Lin F, Shen Z, Tang LN, Zheng SE, Sun YJ, Min DL and Yao Y: KLF8 knockdown suppresses proliferation and invasion in human osteosarcoma cells. Mol Med Rep. 9:1613–1617. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sang W, Zhu L, Ma J, Lu H and Wang C: Lentivirus-mediated knockdown of CTHRC1 inhibits osteosarcoma cell proliferation and migration. Cancer Biother Radiopharm. 31:91–98. 2016. View Article : Google Scholar : PubMed/NCBI
25	Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, et al: Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 464:374–379. 2010. View Article : Google Scholar : PubMed/NCBI
26	Welcker M and Clurman BE: FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 8:83–93. 2008. View Article : Google Scholar : PubMed/NCBI
27	Grim JE, Knoblaugh SE, Guthrie KA, Hagar A, Swanger J, Hespelt J, Delrow JJ, Small T, Grady WM, Nakayama KI and Clurman BE: Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol. 32:2160–2167. 2012. View Article : Google Scholar : PubMed/NCBI
28	Crusio KM, King B, Reavie LB and Aifantis I: The ubiquitous nature of cancer: The role of the SCF(Fbw7) complex in development and transformation. Oncogene. 29:4865–4873. 2010. View Article : Google Scholar : PubMed/NCBI